• Incidence and Severity of Bronchiolitis obliterans syndrome within 2 years from Transplantation
  
• Mortality within 2 years of Transplantation
  
• Need for Change of Immunosuppressive Medication within 2 years of Transplantation
  

• Incidence and severity of Nephrotoxicity within 2 years of transplantation
  
• Incidence and severity of opportunistic infections within 2 years of transplantation
  

Inclusion Criteria:

• Recipient of Single or Bilateral Lung Transplantation
• Informed consent
• Recipients who are able to receive Everolimus at week 3 after Lung Transplantation
• women of childbearing potential must have a negative pregnancy test within 48 hours of enrolment
• women of childbearing potential must use appropriate contraceptive method at enrolment, during the study and up to 8 weeks after the end of the study
• donor must not have relevant pulmonary diseases
• donor must have oxygen partial pressure higher than 300 mmHg at FiO 1.0 and positive end-expiratory pressure of 5 cm H2O.

Exclusion Criteria:

• systemic infection of the donor
• donor: signs or symptoms of aspiration
• donor: severe pulmonary injury or contusion
• donor: malignant neoplasm of the lung
• donor: HIV positive
• recipients who receive immunosuppressive agents not used in this protocol
• recipients who participated within 30 days before study start or are currently participating in another investigational drug trial
• HIV positive recipient
• systemic infection of the recipient
• recipients of combined/ multiple transplantations
• pregnancy of the recipient
• recipients with signs/ Symptoms of impaired wound healing of the pulmonary anastomoses
• recipients who are still on artificial respiration or who are not able to swallow tablets at week 3 after transplantation